MedTrace Logo

Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion

NCT06029998 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-11-28

No results posted yet for this study

Summary

The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion.

The main question\[s\] it aims to answer is if the use of bortezomib will result in a decline in PSA for participants.

Participants will receive a sub-cutaneous injection of bortezomib for up 8 cycles. Each cycle is about 21 days.

Conditions

Interventions

DRUG

Bortezomib

sub-cutaneous injection of bortezomib for 6-8 cycles of treatment.

Sponsors & Collaborators

Principal Investigators

  • Umang Swami, MD, MS · University of Utah

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-11
Primary Completion
2026-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06029998 on ClinicalTrials.gov